Results 21 to 30 of about 15,814 (215)

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

ESC Heart Failure, 2022
Aims In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of
Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P. Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke   +10 more
doaj   +1 more source

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome

Journal of the Saudi Heart Association, 2017
Clinical Research. Presentation type: Poster Presentation. Introduction: Empagliflozin is a potent and selective SGLT2-I used in the treatment of T2DM.
Mahmoud Elrouby, Elvira Toural
doaj   +1 more source

Integrated multi-omics analyses reveal effects of empagliflozin on intestinal homeostasis in high-fat-diet mice

iScience, 2023
Summary: Obesity has become a global epidemic, associated with several chronic complications. The intestinal microbiome is a critical regulator of metabolic homeostasis and obesity.
Junfeng Shi, Hongyan Qiu, Qian Xu, Yuting Ma, Tongtong Ye, Zengguang Kuang, Na Qu, Chengxia Kan, Ningning Hou, Fang Han, Xiaodong Sun   +10 more
doaj   +1 more source

Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet‐Derived Growth Factor–Related Signaling

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events. However, the precise mechanisms beyond glycemic control are not fully understood.
Gwo‐Jyh Chang, Wei‐Jan Chen, Yu‐Juei Hsu, Ying‐Hwa Chen   +3 more
doaj   +1 more source

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. [PDF]

PLoS ONE, 2017
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associated with slower progression of diabetic kidney disease.
David Cherney, Bruce A Perkins, Yuliya Lytvyn, Hiddo Heerspink, María E Rodríguez-Ortiz, Harald Mischak   +5 more
doaj   +1 more source

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease

Biomedicines, 2022
Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of CKD.
Silvie Hojná, Zoe Kotsaridou, Zdeňka Vaňourková, Hana Rauchová, Michal Behuliak, Petr Kujal, Michaela Kadlecová, Josef Zicha, Ivana Vaněčková   +8 more
doaj   +1 more source

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy

Antioxidants
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications.
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky   +3 more
doaj   +1 more source

Chinese Expert Consensus on the Clinical Application of Finerenone in Geriatric Comorbidities

AGING MEDICINE, EarlyView.
Mineralocorticoid receptor (MR) overactivation drives inflammation, oxidative stress, and fibrosis in the heart, kidneys, and vasculature, leading to cardiorenal dysfunction. MR signaling promotes hypertrophy, remodeling, and injury through pathways like oxidative stress and inflammation, resulting in vascular stiffness and progressive organ damage ...
Xiaoming Wang, Cuntai Zhang
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway

Redox Biology, 2022
Mitophagy preserves microvascular structure and function during myocardial ischemia/reperfusion (I/R) injury. Empagliflozin, an anti-diabetes drug, may also protect mitochondria.
Chen Cai, Zhongzhou Guo, Xing Chang, Ziying Li, Feng Wu, Jing He, Tiantian Cao, Kangrong Wang, Nengxian Shi, Hao Zhou, Sam Toan, David Muid, Ying Tan   +12 more
doaj   +1 more source